Conference Coverage

New antibodies, drugs for refractory and relapsed myeloma are effective in patients over 65


Key clinical point: Recently approved monoclonal antibodies and drugs for treating refractory/relapsed multiple myeloma work well for patients aged 65-75 years.

Major finding: The hazard ratios for progression-free survival were largely similar for patients younger than age 65 years and patients aged 65 and older.

Data source: Meta-analysis of eight phase 3 randomized trials.

Disclosures: Dr. Landre reported having no financial conflicts of interest.


AT ESMO 2017


– Patients with refractory/relapsed multiple myeloma had similar rates of progression-free survival (PFS) whether they were younger than age 65 or 65 years and older, based on the results of eight recent phase 3 trials in an analysis presented at the European Society for Medical Oncology Congress.

   Comments ()

Next Article: